03rd week of 2022 patent applcation highlights part 10 |
Patent application number | Title | Published |
20220016183 | EXOSOME AND VARIOUS USES THEREOF - The present invention relates to a novel exosome comprising glucosamine, glucosamine derivatives, or salts thereof. The exosome provided by the present invention has an excellent anti-inflammatory effect, and thus can effectively prevent, ameliorate, or treat various inflammatory diseases. The exosome also has an excellent effect of treating intestinal diseases, improving the skin, treating wounds, or treating hair loss. | 2022-01-20 |
20220016184 | COMPOSITIONS COMPRISING BACTERIAL STRAINS - The invention provides compositions comprising bacterial strains for treating and preventing brain injury. | 2022-01-20 |
20220016185 | COMPOSITIONS AND METHODS COMPRISING BACTERIA FOR IMPROVING BEHAVIOR IN NEURODEVELOPMENTAL DISORDERS - Some embodiments include bacterial species for use in treatment of one or more autism spectrum disorder (ASD), and/or schizophrenia symptoms in a subject in need thereof. The bacterial species can include | 2022-01-20 |
20220016186 | SYNBIOTIC COMPOSITION FOR TREATMENT OF INFECTIONS IN ALLERGIC PATIENTS - The invention concerns the use of prebiotics and probiotics for the treatment of infections in allergic patients. | 2022-01-20 |
20220016187 | LACTOBACILLUS PARACASEI AND ITS APPLICATION IN PREPARATION OF MEDICINE FOR TREATING ULCERATIVE COLITIS - A strain of | 2022-01-20 |
20220016188 | METHODS AND COMPOSITIONS FOR TREATING CANCER - Described herein are methods and compositions for treating cancer and for predicting a subjects' response to combination checkpoint inhibitor therapy. Aspects of the disclosure relate to a method of treating cancer and/or reducing toxicity to a therapy in a subject comprising administering to the subject a composition comprising at least one isolated or purified population of bacteria belonging to one or more of the genera | 2022-01-20 |
20220016189 | WEISSELLA BACTERIA-DERIVED NANOVESICLE AND USE THEREOF - Provided are vesicles derived from bacteria of the genus | 2022-01-20 |
20220016190 | DELIVERY VEHICLE - The invention relates in one aspect to a pharmaceutical composition comprising a nucleic acid delivery vehicle for delivering a deliverable nucleic acid into a bacterial cell, wherein the delivery vehicle comprises a deliverable nucleic acid packaged into one or more bacteriophage coat proteins, and wherein the delivery vehicle is capable of infecting the bacterial cell to introduce the deliverable nucleic acid into the cell, following which the deliverable nucleic acid is capable of forming a plasmid in the cell and being transmitted to one or more different bacterial cells by conjugation and not by infection. Compositions including a pharmaceutical composition comprising the delivery vehicle, and methods involving use or manufacture of the delivery vehicle, are also disclosed. | 2022-01-20 |
20220016191 | SIMULTANEOUS DELIVERY OF CANCER TREATMENT PROGRAMS TO TUMOR AND IMMUNE CELLS - Disclosed herein are genetically modified herpesviruses for the treatment of cancer. Also provided are methods of treating cancer using genetically modified herpesviruses. | 2022-01-20 |
20220016192 | Platform Oncolytic Vector for Systemic Delivery - This disclosure provides a modified oncolytic virus that can contain modifications in the viral genome and exogenous nucleic acids coding for proteins. The modified oncolytic virus can be utilized as a platform vector for systemic delivery. | 2022-01-20 |
20220016193 | ANTIBACTERIAL AND ANTIVIRUS COMPOSITION COMPRISING Extract of CANNABIS SATIVA L. - The present disclosure relates to an antibacterial and antiviral composition containing an extract of | 2022-01-20 |
20220016194 | ANTIVIRAL COMPOSITIONS AND METHODS - In general, embodiments of the present invention provide antiviral essential oil compositions, and methods of making and using the same. Essential oil compositions can include one or more essential oils, such as thyme essential oil, oregano essential oil, and/or cinnamon essential, optionally in combination with one or more emulsifiers. Essential oil compositions can be in the form of an emulsion and have droplet sizes less than about 25 microns. The use of these compositions in organisms and systems provides beneficial antiviral effects, among others. | 2022-01-20 |
20220016195 | SINGLE-DOSE USE OF A COMPOSITION COMPRISING A PARTICULAR MIXTURE OF GRAPE EXTRACT AND BLUEBERRY EXTRACT - The invention relates to the use of a composition comprising at least one mixture of molecules obtained from | 2022-01-20 |
20220016196 | Aloe Based Compositions Comprising Polysaccharides and Polyphenols for Regulation of Homeostasis of Immunity - Compositions used and methods are disclosed for regulation of immunity homeostasis including a combination of an | 2022-01-20 |
20220016197 | ZINGIBER ZERUMBET EXTRACT FOR COMBATING DANDRUFF - The present invention relates to the use of an extract of | 2022-01-20 |
20220016198 | METHODS FOR DISRUPTING BIOFILMS - The present invention provides methods for disrupting biofilms and/or preventing the formation of biofilms along with medical items that contain a coating or covering made of compositions for achieving such disruption or prevention. In particular, the compositions of the present invention provide random-sequence peptide mixtures for use in disrupting bacterial biofilms; the random-sequence peptides having hydrophobic and/or cationic amino acids, wherein the ratio of the total hydrophobic and cationic amino acids in the mixture is predefined. | 2022-01-20 |
20220016199 | HYDROGEL COMPOSITION AND ASSOCIATED METHOD OF USE - The invention provides a composition and pharmaceutical formulation including a peptide immobilized in a hydro gel. Compositions and formulations of the invention are useful in reducing the size, severity or duration of a wound, ameliorating of one or more symptoms associated with a wound without necessarily curing the wound, or lessening in the growth or severity of a wound. Compositions and formulations of the invention are particularly useful in the treatment of a wound associated with diabetes, such as a diabetic ulcer. | 2022-01-20 |
20220016200 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CYSTIC FIBROSIS - The invention relates to a pharmaceutical composition comprising a polymyxin or a pharmaceutically acceptable salt or prodrug thereof, teicoplanin and/or fusidic acid or a pharmaceutically acceptable salt or prodrug thereof, and a pharmaceutically acceptable excipient and to ready-to-use kits for the preparation of said pharmaceutical composition. | 2022-01-20 |
20220016201 | DAPTOMYCIN FORMULATIONS CONTAINING A COMBINATION OF SORBITOL AND MANNITOL - In an aspect, a method of manufacture of a pharmaceutically acceptable solid composition containing daptomycin includes drying an aqueous solution containing (i) water, (ii) the daptomycin, (iii) sorbitol in an amount of about 1.2 wt. % to about 9.0 wt. % of total volume of the aqueous composition and (iv) mannitol in an amount of about 0.6 wt. % to about 9.5 wt. % of total volume of the aqueous composition to form the solid composition. The drying can include an sublimation drying of about −25° C. to about 50° C. for a time period of about 15 hours to about 120 hours, most preferably about 15° C. for about 20 hours, optionally preceded and/or followed by one or more additional drying steps. Other aspects are the solid composition containing the daptomycin and also methods of treating a bacterial infection including administering a pharmaceutically acceptable product made by reconstituting the solid composition. | 2022-01-20 |
20220016202 | CARTILAGE-HOMING PEPTIDES - Peptides that home, target, migrate to, are directed to, are retained by, or accumulate in and/or binds to the cartilage of a subject are disclosed. Pharmaceutical compositions and uses for peptides or peptide-active agent complexes comprising such peptides are also disclosed. Such compositions can be formulated for targeted delivery of a drug to a target region, tissue, structure or cell in the cartilage. Targeted compositions of the disclosure can deliver peptide or peptide-active agent complexes to target regions, tissues, structures or cells targeted by the peptide. | 2022-01-20 |
20220016203 | COMPOSITIONS AND METHODS FOR PREVENTION AND REDUCTION OF METASTASIS - Compositions and methods for the prevention or reduction of metastasis are provided. Such compositions and methods include increasing the level or expression of HAPLN 1. | 2022-01-20 |
20220016204 | Native whey protein for improving intestinal maturation - The invention concerns native whey protein for use in (a) improving intestinal maturation; and/or (b) reducing and/or preventing intestinal permeability. The inventors found that native whey protein provides a beneficial effect on intestinal maturation and permeability. | 2022-01-20 |
20220016205 | METHODS OF OVERCOMING RESISTANCE TO IMMUNE CHECKPOINT INHIBITORS - Provided herein are methods of using BMP7 levels as a marker for the selection of patients, such as non-small cell lung cancer patients, who will clinically respond to combination therapy comprising a BMP7 inhibitor and an immune checkpoint therapy, such as an anti-PD1 therapy and/or an anti-CTLA-4 therapy. Also provided are methods of treating the selected patients with a combination of a BMP7 inhibitor and an immune checkpoint therapy. | 2022-01-20 |
20220016206 | ISOFORM NELL-1 PEPTIDE - This application is drawn to a method of using an isoform NELL-1 peptide, and compositions thereof for bone formation or for treating, preventing, or ameliorating osteoporosis. | 2022-01-20 |
20220016207 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING GASTROINTESTINAL AND GASTRIC CANCER - A pharmaceutical composition contains an antibody or a fragment thereof specific for COL6A3 for the treatment of a cancer. A method of treating a cancer includes administering to a subject in need thereof the pharmaceutical composition. A kit includes a container that contains the pharmaceutical composition. A method of producing an antibody or a fragment thereof against a peptide or a WIC/peptide complex. A method for detecting a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a radioisotope and detecting a signal from the radioisotope in the subject. A method for treating a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a toxin. | 2022-01-20 |
20220016208 | METHODS AND AGENTS TO TREAT INFERTILITY IN FEMALES - Described are novel female fertility therapies. A first aspect of the invention is directed to therapies that include FSH lowering methodologies to prevent and/or treat egg infertility. A second aspect of the invention is directed to agents that bind to activin, bind to receptors that bind activin, or that otherwise disrupt activin signaling (collectively referred to herein as “activin pathway modifier agents” or “APM agents”) and methods of utilizing these agents to prevent and/or treat egg infertility. A third aspect of the invention is directed to methods of administering an effective amount of an APM agent to a subject to increase oocyte yield and/or ovarian reserve. All three aspects of the invention may be used in humans and in animals. Additional aspects of the invention include therapeutic drug kits for treatment of humans and animals based on the methodologies described above. | 2022-01-20 |
20220016209 | NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS INCLUDING GASTROINTESTINAL AND GASTRIC CANCER - A pharmaceutical composition contains an antibody or a fragment thereof specific for COL6A3 for the treatment of a cancer. A method of treating a cancer includes administering to a subject in need thereof the pharmaceutical composition. A kit includes a container that contains the pharmaceutical composition. A method of producing an antibody or a fragment thereof against a peptide or a WIC/peptide complex. A method for detecting a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a radioisotope and detecting a signal from the radioisotope in the subject. A method for treating a diseased tissue includes administering to a subject in need thereof an antibody or a fragment thereof conjugated to a toxin. | 2022-01-20 |
20220016210 | AFLIBERCEPT FORMULATIONS AND USES THEREOF - Ophthalmic formulations comprising aflibercept are disclosed that are suitable for a method of treatment of an eye disorder or disease by intravitreal or topical administration. | 2022-01-20 |
20220016211 | FGF-21 CONJUGATE FORMULATIONS - The present application provides pharmaceutical formulations comprising PEGylated FGF-21, e.g., a FGF-21 conjugate, and one or more stabilizers such as the chelator DPTA. The formulations can be can further stabilized by including a surfactant such as polysorbate 80 and/or adjusting the pH to about 7.1. Also provided are methods of manufacture, methods of treatment, and kits. | 2022-01-20 |
20220016212 | METHODS OF TREATING CHEMOTHERAPY INDUCED NEUTROPENIA USING FIXED DOSES OF G-CSF PROTEIN COMPLEX - This disclosure provides a method of preventing, alleviating, or treating a condition (i.e., neutropenia) in a patient in need thereof, the condition characterized by compromised white blood cell production in the patient. The method includes administering to the patient a therapeutically effective amount of a protein complex comprising a modified human granulocyte-colony stimulating factor (hG-CSF) covalently linked to an immunoglobulin Fc region via a non-peptidyl polymer at a fixed dose regardless of the patient's weight. | 2022-01-20 |
20220016213 | Methods and Compositions for Treating Osteoarthritis - Methods for treating a human suffering from osteoarthritis are provided. Aspects of the methods include intra-articularly administering to the human a dosage comprising a nucleic acid coding sequence for a human interleukin-1 receptor antagonist (IL-1Ra) to treat the human suffering from osteoarthritis. Also provided are compositions for use in practicing the methods. | 2022-01-20 |
20220016214 | HIV Treatment Compositions And Methods - HIV treatment, and especially treatment of latent infected CD4 cells, can be significantly improved using a kick-and-kill approach that employs an immune stimulation component and/or HDAC inhibition as one treatment component, and that may also include a second component in which a vaccine composition, various NK cells, CAR-T cells, and/or broadly neutralizing antibodies are administered. | 2022-01-20 |
20220016215 | GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF - The present disclosure provides GIF receptor agonist peptide compounds having an activating action on GIF receptors and use of the GIF receptor agonist peptide as a medicament for the treatment and/or prevention of emesis. Specifically, a GIF receptor agonist peptide containing a sequence represented by the formula (I) or a salt thereof, and a medicament comprising the same are N provided. Formula (I) P | 2022-01-20 |
20220016216 | SOLID GLP-1 DERIVATIVE COMPOSITIONS FOR ORAL ADMINISTRATION - The present invention relates to solid compositions for oral administration comprising (i) a GLP-1 derivative and the SGLT2 inhibitor dapagliflozin or (ii) a GLP-1 derivative and a salt of NAC in combination with an SGLT2 inhibitor. | 2022-01-20 |
20220016217 | COMBINATION OF AN INSULIN AND A GLP-1-AGONIST - The invention relates to a drug comprising at least one insulin and at least one GLP-1 receptor agonist. | 2022-01-20 |
20220016218 | LIPOPHILIC PEPTIDE PRODRUGS - The present invention relates to methods of preparing peptide-based prodrugs having enhanced oral bioavailability and intestinal penetration. Said prodrugs are characterized in improved lipophilicity, reduced electric charge and tendency to undergo biotransformation through enzymatic reaction (e.g. in the blood stream) to form biologically active peptides. | 2022-01-20 |
20220016219 | Means and Methods to Treat Diabetes - The present application relates to a pharmaceutical composition for use in a method of treating diabetes in a human or animal subject in need thereof, to transplantation devices comprising the pharmaceutical composition of the present invention and to methods of treating diabetes using the pharmaceutical composition and transplantation device of the present invention. | 2022-01-20 |
20220016220 | COMPOSITION FOR THE TREATMENT OF SKIN LESIONS - The present invention relates to the association between the lactoferrin protein and the mesoglycan, in particular for the use in the therapy of skin lesions of different kinds and degrees. | 2022-01-20 |
20220016221 | TREATMENT OF SYMPTOMS OF TRAUMATIC BRAIN INJURY - Method of treating or reducing a symptom of traumatic brain injury (TBI) in a subject, comprising administering to the subject a therapeutically-effective amount of botulinum neurotoxin. Composition for use in treating or reducing a symptom of TBI in a subject comprising botulinum neurotoxin. Computer system programmed to receive information related to a subject's response to administration of botulinum neurotoxin, store that response in a database, and transmit the response to a medical practitioner. Non-transitory computer-readable storage medium storing instructions that, when executed by a computer system, causes the computer system to perform the aforementioned steps. | 2022-01-20 |
20220016222 | SPHINGOID COMPOUNDS FOR PROPHYLAXIS AND/OR THERAPY OF CORONAVIRIDAE INFECTION - Provided are processes for the prevention or treatment of infection by SARS-CoV-2. Some aspects provide administration of a sphingoid compound, optionally sphingosine, an active ingredient that activates generation of a sphingoid base, optionally of sphingosine; or an active agent that inhibits the degradation of a sphingoid base, optionally of sphingosine, to a subject such as a human. By increasing the local concentration of sphingosine in a subject or an area of a subject to which the composition is administered such as the airways, nose or interior of the nose or portion thereof, the ability or SARS-CoV-2 to infect the subject or cells thereof is reduced thereby treating of preventing infection by the virus. | 2022-01-20 |
20220016223 | Functionalized Enzyme-Powered Nanomotors - The present invention provides an enzyme-powered nanomotor, comprising a particle with a surface, an enzyme, and a heterologous molecule; characterized in that the enzyme and the heterologous molecule are discontinuously attached over the whole surface of the particle. The invention also provides the nanomotor for use in therapy, diagnosis and prognosis, in particular, for the treatment of cancer. Additionally, the invention provides the use of the nanomotor for detecting an analyte in an isolated sample. | 2022-01-20 |
20220016224 | METHODS AND COMPOSITIONS FOR TREATING AGING-ASSOCIATED CONDITIONS - Methods of treating an adult mammal for an aging-associated condition are provided. Aspects of the methods include enhancing a TIMP activity, e.g., a TIMP2 activity, in the mammal in a manner sufficient to treat the adult mammal for the aging-associated condition. Also provided are compositions for use in practicing methods of the invention. A variety of aging-associated conditions may be treated by practice of the methods, which conditions include cognitive impairments. | 2022-01-20 |
20220016225 | VACCINE COMPOSITIONS AND ADJUVANT - The immune response of an animal to a target immunogen may be enhanced by use of an adjuvant which includes low concentrations of killed cells of | 2022-01-20 |
20220016226 | Peptide - There is provided a peptide which is capable of binding to an MHC molecule in vitro and being presented to a T cell without antigen processing (i.e. an apitope) which peptide comprises all or a portion of the following proteolipid protein (PLP) peptides: PLP 36-61: HE ALTGTEKLIET YF SKN YQD YEYLI (SEQ ID NO. 1) PLP 179-206: TWTTCQSIAFPSKTSASIGSLCA-DARMY (SEQ ID NO. 2) PLP 207-234: GVLPWNAFPGKVCGSNLLSICKTAEFQM (SEQ ID NO. 3). There is also provided the use of such a peptide in a pharmaceutical composition and a method to treat and/or prevent a disease using such a peptide. | 2022-01-20 |
20220016227 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST HEPATOCELLULAR CARCINOMA (HCC) AND OTHER CANCERS - The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules. In particular, the present invention relates to several novel peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses or as targets for the development of pharmaceutically/immunologically active compounds and cells. | 2022-01-20 |
20220016228 | Consensus Prostate Antigens, Nucleic Acid Molecule Encoding The Same And Vaccine And Uses Comprising The Same - Provided herein are consensus amino acid sequences of prostate antigens that are capable of breaking tolerance in a targeted species, including PSA, PSMA, STEAP and PSCA antigens. Also provided are nucleic acid sequences that encode one or more consensus amino acid sequences of prostate antigens PSA, PSMA, STEAP and PSCA, as well as genetic constructs/vectors and vaccines expressing the sequences. Also provided herein are methods for generating an autoimmune response against prostate cancer cells by administering one or more of the vaccines, proteins, and/or nucleic acid sequences that are provided. | 2022-01-20 |
20220016229 | Immunogenic Multiple Hetero-Antigen Polysaccharide-Protein Conjugates and uses thereof - The present invention relates to new glycoconjugates comprising | 2022-01-20 |
20220016230 | METHOD OF PRODUCING PHARMACEUTICAL COMPOSITIONS COMPRISING IMMUNOGENIC CHIKUNGUNYA VIRUS CHIKV-DELTA5NP3 - The present invention relates to a process for producing an immunogenic live attenuated Chikungunya virus, as well as pharmaceutical compositions comprising the same. | 2022-01-20 |
20220016231 | HEPATITIS B VIRUS VACCINE AND USES THEREOF - A hepatitis B vims (HBV) vaccine particle is described, including a recombinant HBV surface antigen including L surface protein; optionally M surface protein; and optionally S surface protein; wherein the molar percentage of L surface protein to the sum of L, M, and S surface proteins is at least about 1 mole %, 8 mole %, 10 mole %, 20 mole %, 30 mole %, 40 mole %, or 50 mole %. Methods of making the same and methods of treating or preventing HBV infection in a subject using the same are also described. | 2022-01-20 |
20220016232 | LIVE ATTENUATED INFLUENZA B VIRUS COMPOSITIONS METHODS OF MAKING AND USING THEREOF - The NS1 protein of influenza virus is a key virulent element with multi-functional roles in virus replication and acts as a strong interferon (IFN) antagonist. A live attenuated virus (LAIV) is provided using a master backbone, which contains the influenza B (HK8038) virus and includes a deletion of the NSI coding region (DelNS1). The LAIV is based on novel adaptive mutations, which support DelNS1 influenza B live attenuated virus (LAIV) replication in vaccine producing cells. DelNS1 influenza B LAIV shows spontaneous cold adaption with preference to grow at 30-33° C. but restriction at 37-39° C. The LAIV can be used to protect a subject, against a lethal challenge of antigenic distant influenza B viruses. DelNS1 LAIV with adaptive mutations for growing in vaccine producing systems is an important strategy for making highly attenuated and immunogenic live attenuated influenza vaccines with the ability to induce broad cross protective immunity for seasonal influenza. | 2022-01-20 |
20220016233 | IDENTIFYING PATIENT POPULATIONS VULNERABLE TO VIRAL INFECTION AND METHODS OF INDUCING HETEROLOGOUS IMMUNITY IN SAME - This application relates to methods for assessing patient populations and determining subpopulations vulnerable to viral infection, methods of reducing the risk of infection and/or inducing heterologous immunity to said viral infection. | 2022-01-20 |
20220016234 | ANTI COVID-19 THERAPIES USING NUCLEOCAPSID AND SPIKE PROTEINS - Disclosed herein are methods for inducing immunity against a severe acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV2) in a patient in need thereof. The method comprises administering a vaccine composition comprising a self-adjuvanted SARS-CoV2 Spike (S) RNA-based vaccine (AAHI-SC2), followed by administering a replication defective adenovirus (hAd5) vaccine composition, wherein the adenovirus comprises an E1 gene region deletion and an E2b gene region deletion. | 2022-01-20 |
20220016235 | CORONAVIRUS VACCINE COMPOSITIONS, METHODS, AND USES THEREOF - The present disclosure relates in some aspects to immunogenic compositions including recombinant peptides and proteins comprising coronavirus viral antigens and immunogens, e.g., coronavirus S protein peptides. In some aspects, the immunogenic composition comprises a secreted fusion protein comprising a soluble coronavirus viral antigen joined by in-frame fusion to a C-terminal portion of a collagen which is capable of self-trimerization to form a disulfide bond-linked trimeric fusion protein. In some aspects, the immunogenic compositions provided herein are useful for generating an immune response, e.g., for treating or preventing a coronavirus infection. In some aspects, the immunogenic compositions provided herein may be used in a vaccine composition, e.g., as part of a prophylactic and/or therapeutic vaccine. Also provided herein are methods for producing the recombinant peptides and proteins, prophylactic, therapeutic, and/or diagnostic methods, and related kits. | 2022-01-20 |
20220016236 | RECOMBINANT PORCINE PARVOVIRUS ANTIGENIC PROTEIN AND USE THEREOF - The present invention provides: a recombinant expression vector comprising a gene encoding a porcine parvovirus VP2 protein; a recombinant plant or a recombinant insect cell transformed with the vector; and a vaccine composition for a porcine parvovirus and a composition for diagnosing porcine parvovirus, both of which contain a porcine parvovirus VP2 protein obtained from the recombinant plant or the recombinant insect cell. When the recombinant plant or recombinant insect cell of the present invention is used, the porcine parvovirus antigenic protein can be produced with high efficiency, and the porcine parvovirus antigenic protein production method using the recombinant plant or recombinant insect cell has excellent safety and stability compared with other antigen production methods. | 2022-01-20 |
20220016237 | RNA REPLICON VACCINES AGAINST HBV - Nucleic acid molecules encoding hepatitis B virus (HBV) surface antigens, HBV core antigens, and HBV polymerase antigens, and related combinations, are described. Also described are vectors, such as DNA plasmids or viral vectors, and RNA replicons, expressing the HBV antigens, and pharmaceutical compositions containing the expression vectors. Methods of inducing an immune response against HBV or treating an HBV-induced disease, particularly in individuals having chronic HBV infection, using the pharmaceutical compositions of the invention are also described. | 2022-01-20 |
20220016238 | METHODS FOR MAKING MIXED ALLERGEN COMPOSITIONS - Methods of making mixed allergen drug products are provided, wherein the mixed allergen drug products are of known potency and identity and substantially free of replication viable organisms. | 2022-01-20 |
20220016239 | METHOD FOR TREATING CANCER USING ARTIFICIAL ADJUVANT CELL (aAVC) - [Problem to be Solved] | 2022-01-20 |
20220016240 | IMMUNE PRIMING TO ACCELERATE/ENHANCE IMMUNE RESPONSE THROUGH ADMINISTRATION OF NATURAL IMMUNE MODULATOR - A method and compound for altering the status of both innate and adaptive immune pathways in both animals and humans are disclosed. The status alteration results in the immune response being primed whereby an accelerated and more robust response is generated when the animal or human is challenged by pathogens that lead to a wide range of disease states. The disclosed method utilizes a compound derived from a lipopolysaccharide (LPS) of gram-negative bacteria. The compound itself is a natural product with no observed adverse environmental impact. By priming the immune pathways according to the disclosed inventive concept, the severity of various disease states can be reduced, can be resolved more quickly, or can be avoided entirely. | 2022-01-20 |
20220016241 | COMPOSITIONS AND METHODS FOR REDUCING ANTIGEN-SPECIFIC IMMUNOGENICITY - Provided are methods for inducing immune tolerance to antigens including therapeutic antigens. The present methods comprise administering to an individual OPLS or other lipidic compositions and the antigen, either in a single formulation or as separate formulations where the separate formulations are administered concomitantly or sequentially. | 2022-01-20 |
20220016242 | Halogenated Xanthenes as Vaccine Adjuvants - A method of inducing a Type I interferon response in a mammalian subject that presents with a microbial infection, cancerous tumor or hematological malignancy that comprises administering an amount of a halogenated xanthene as discussed above, effective to induce the Type I interferon response. A method of enhancing a mammalian immunogen-specific immune response that comprises contacting mammalian cells, in vivo or present in a mammalian cell growth supporting medium, with an adjuvant-effective amount of a halogenated xanthene, and an immunogen to which that response is to be enhanced. A mammalian HX compound-adjuvanted vaccine composition that contains an immunogen present in a vaccine-effective amount along with an adjuvant-effective amount of a halogenated xanthene (HX) compound and one or more excipients present at about 0.001% by weight to 10% by weight of the vaccine composition dissolved or dispersed in a pharmaceutically acceptable diluent. | 2022-01-20 |
20220016243 | METHODS FOR TREATMENT OF CANCER WITH AN ANTI-TIGIT ANTAGONIST ANTIBODY - The present invention relates to methods, uses, and compositions for the treatment of cancer (e.g., a lung cancer; a cervical cancer; a breast cancer; a head and neck cancer; a liver cancer; a bladder cancer; a gastric cancer; an esophageal cancer; a pancreatic cancer; a kidney or renal cancer; a melanoma; an ovarian cancer; or a colorectal cancer). More specifically, the invention concerns the treatment of patients having cancer with an anti-TIGIT antagonist antibody, including treatment with an anti-TIGIT antagonist antibody in a combination therapy. | 2022-01-20 |
20220016244 | PHARMACEUTICAL ANTI-TNF-ALPHA ANTIBODY FORMULATION - Provided are improved storage-stable liquid pharmaceutical antibody formulations. In particular, liquid aqueous pharmaceutical formulations of Adalimumab based on alternative buffer systems to citrate/phosphate and pharmaceutical containers like auto-injection devices containing the same are described. | 2022-01-20 |
20220016245 | CONJUGATE OF BIOTIN-MODIFIED DIMER AND PHTHALOCYANINE DYE - It is an object of the present invention to provide a conjugate of a biotin-modified dimer and a phthalocyanine dye, which is used in photoimmunotherapy. The present invention provides a conjugate of a compound represented by the following formula (1) or a salt thereof and a phthalocyanine dye: | 2022-01-20 |
20220016246 | HYPERTONIC ANTIMICROBIAL THERAPEUTIC COMPOSITIONS - Therapeutic compositions, primarily for topical application, and methods of making and using the composition. Pharmaceutical compositions formulated for specific forms of administration are also provided. | 2022-01-20 |
20220016247 | DRY POWDER INHALATION FORMULATION AND ITS USE FOR THE THERAPEUTIC TREATMENT OF LUNGS - A dry powder inhalation formulation includes at least one active pharmaceutical ingredient (API) and a lipid matrix having at least one triglyceride chosen in the group consisting of monohydroxystearin, dihydroxystearin, trihydroxystearin and their mixture and its manufacturing method. | 2022-01-20 |
20220016248 | BRANCHED AMINO ACID SURFACTANTS FOR USE IN HEALTHCARE PRODUCTS - Healthcare formulations, including, inventive surfactants, Active ingredient formulated as solids, liquids, or emulsions. The present disclosure provides formulations of healthcare products, such as: prescription drugs, over the counter drugs; minerals, herbal, and/or vitamin supplements; drugs administered in hospitals, clinics, physician's office, and places of palliative care; vaccines, tissue, organ, and cell transplants and/or grafts and/or infusions; and wound care formulations including topical ointments, lotions, cleaners, wipes, bandages, and dressings. The Active may be included in the formulations as a solute, a solvent, a particle, or an oil immiscible component of the formulation. The Active may be included in tablets, capsules, tinctures, liquids, or emulsions. Inventive healthcare formulations include formulations suitable for administration orally, topically, and/or by injection. | 2022-01-20 |
20220016249 | IL-2 Conjugates and Methods of Use Thereof - Disclosed herein are compositions, kits, and methods comprising interleukin (IL) conjugates (e.g., IL-2 conjugates) useful for the treatment of one or more indications. Also described herein are pharmaceutical compositions and kits comprising one or more of the interleukin conjugates (e.g., IL-2 conjugates). | 2022-01-20 |
20220016250 | PEPTIDE HYDROGELS FOR DELIVERY OF IMMUNOSUPPRESSIVE DRUGS AND USES THEREOF - Compositions that include a cationic peptide hydrogel and an immunosuppressive small molecule drug are described. The small molecule drug is crystallized and dispersed in the peptide hydrogel to allow for slow release of the drug. Methods of inhibiting allograft rejection and treating autoimmune-mediated organ damage by local administration of the peptide hydrogel compositions are described. | 2022-01-20 |
20220016251 | LYMPHATIC MEDIATED TRANSPORT-BASED TRIGLYCERIDE PRODRUG, AND PREPARATION METHOD THEREFOR - In the field of medical technologies, there is a triglyceride prodrug based on lymphatic-mediated transport, particularly a triglyceride prodrug with different linking chains for lymphatic-mediated transport, and a method for preparing the same and use thereof in drug delivery. The prodrugs are linked by different linking bonds and methods for synthesizing the same. The structures of the prodrugs are as follows: | 2022-01-20 |
20220016252 | IMMUNO ONCOLOGY COMBINATION THERAPY WITH IL-2 CONJUGATES AND ANTI-EGFR ANTIBODIES - Disclosed herein are methods for treating a cancer in a subject in need thereof, comprising administering IL-2 conjugates in combination with an anti-EGFR antibody. | 2022-01-20 |
20220016253 | L-DOPA AND/OR DOPA DECARBOXYLSE INHIBITORS CONJUGATED TO SUGAR FOR THE TREATMENT OF DOPAMINE-RESPONSIVE DISORDERS - The present invention provides conjugates comprising a sugar such as mannitol and one or more L-DOPA and/or DOPA decarboxylse inhibitors including, inter alia, L-DOPA, carbidopa, benserazide, or a combination thereof, wherein the sugar is conjugated to the carboxyl group of the L-DOPA and/or DOPA decarboxylse inhibitor/ s) via a hydroxyl group of the sugar. The present invention further provides related pharmaceutical compositions and methods of producing the conjugates, as well as methods of use for treating medical disorders responsive to dopamininergic stimulation such as movement disorders including, inter alia, Parkinson's Disease. | 2022-01-20 |
20220016254 | CONJUGATES OF FUSION PROTEINS OF GLP-1 AND FGF21 - The present disclosure provides conjugates of polypeptides comprising GLP-1, polypeptide linker and FGF21. Pharmaceutical compositions comprising the same and methods of treating diseases are also provided. | 2022-01-20 |
20220016255 | PHARMACEUTICAL COMPOSITION - Provided is a method for suppressing the generation of diclofenac lactam from a compound represented by a formula (1) in the description, including allowing the compound of the formula (1) and a component (A) that is at least one type of compound selected from the group consisting of a nonionic surfactant, a hydroxyalkylated cyclodextrin, a C1 to C3 mono-alcohol, a C2 to C3 di-alcohol, a C3 to C6 tri-alcohol, a polyalkylene glycol, a γ-lactone, polyvinylpyrrolidone, a chlorogenic acid, and an alkyl sulfate ester, and salts thereof to coexist. A method for producing a pharmaceutical composition containing a compound represented by the formula (1) and a component (A), and a pharmaceutical composition which is a product produced thereby are also provided. | 2022-01-20 |
20220016256 | METHODS, DEVICE AND REAGENTS TO TREAT ALLERGY AND AUTOIMMUNE DISEASE - The present disclosure provides compositions for inducing immune tolerance and methods to modify antigen to treat allergy and autoimmune disease. Disclosed are compositions, and related methods, comprising APC presentable antigens and immunosuppressants that provide tolerogenic immune responses specific to antigen. In some embodiments, the composition is in a skin patch. | 2022-01-20 |
20220016257 | ANTI-CDH6 ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE - An object of the present invention is to provide an antibody specifically binding to CDH6 and having a high internalization activity, an antibody-drug conjugate comprising the antibody and a high antitumor activity, a pharmaceutical product having the antibody-drug conjugate and having a therapeutic effect on a tumor, a method for treating a tumor using the antibody, the antibody-drug conjugate or the pharmaceutical product, and the like. | 2022-01-20 |
20220016258 | ANTIBODY DRUG CONJUGATES (ADCS) HAVING ENZYMATICALLY CLEAVABLE GROUPS - The invention relates to novel binder-drug conjugates (ADCs) having improved properties, to active metabolites of these ADCs and to processes for their preparation. The present invention furthermore relates to the use of these conjugates for the treatment and/or prevention of diseases and to the use of these conjugates for preparing medicaments for treatment and/or prevention of diseases, in particular hyperproliferative and/or angiogenic disorders such as, for example, cancer diseases. | 2022-01-20 |
20220016259 | COMBINATION THERAPY WITH AN ANTI-CD25 ANTIBODY-DRUG CONJUGATE - The present disclosure relates to combination therapies for the treatment of pathological conditions, such as cancer. In particular, the present disclosure relates to combination therapies comprising treatment with an Antibody Drug Conjugate (ADC) and a secondary agent. | 2022-01-20 |
20220016260 | ANTIBODY COMPRISING A GLUTAMINE-CONTAINING LIGHT CHAIN C-TERMINAL EXTENSION, CONJUGATES THEREOF, AND METHODS AND USES - An antibody has a glutamine-containing extension at the C-terminus of a light chain thereof, making it suitable for conjugation via transglutaminase-mediated transamidation. | 2022-01-20 |
20220016261 | PYRROLOBENZODIAZEPINE-ANTIBODY CONJUGATES - The present disclosure relates to pyrrolobenzodiazepines (PBDs) having a labile C2 or N10 protecting group in the form of a linker to an antibody. | 2022-01-20 |
20220016262 | MATERIALS AND METHODS FOR DELIVERING NUCLEIC ACIDS TO COCHLEAR AND VESTIBULAR CELLS - Provided herein are materials and methods for efficiently delivering nucleic acids to cochlear and vestibular cells. | 2022-01-20 |
20220016263 | FABRY DISEASE GENE THERAPY - There is described a nucleic acid molecule comprising a nucleotide sequence encoding for a functional α-galactosidase A protein wherein the nucleotide sequence has at least 85% identity to the sequence of SEQ ID NO. 1. Also described is a vector, host cell or transgenic animal comprising the nucleic acid molecule; and a pharmaceutical composition comprising the nucleic acid molecule or the vector. Further, the use of the nucleic acid molecule in a method of treating Fabry disease is described. | 2022-01-20 |
20220016264 | AAV VIRIONS WITH DECREASED IMMUNOREACTIVITY AND USES THEREFOR - Methods of making and using recombinant AAV virions with decreased immunoreactivity are described. The recombinant AAV virions include mutated capsid proteins or are derived from non-primate mammalian AAV serotypes and isolates that display decreased immunoreactivity relative to AAV-2. | 2022-01-20 |
20220016265 | MESSENGER RNA THERAPY FOR TREATMENT OF OCULAR DISEASES - The present invention provides, among other things, a method of ocular delivery of messenger RNA (mRNA), comprising administering into an eye of a subject in need of delivery a composition comprising an mRNA encoding a protein, such that the administration of the composition results in expression of the protein encoded by the mRNA in the eye. | 2022-01-20 |
20220016266 | SENSE INDICATOR COMPOSITION - Compositions, kits, and methods for indicating a symptom of a disease. The composition may include one or more components having a taste or smell property as an indicator of a symptom of a disease. When applied to a user's tongue or mouth, detection or lack of detection of the taste or smell property may indicate a person has temporarily lost his/her sense of smell or taste as a result of a disease, particularly COVID-19 infection or exposure. | 2022-01-20 |
20220016267 | NANOPARTICLES FOR CANCER DETECTION - Disclosed herein, inter alia, are methods for detecting cancer using nanoparticles. | 2022-01-20 |
20220016268 | SKIN-BASED TESTING FOR DETECTION OF CELL-MEDIATED IMMUNE RESPONSES TO SARS-COV-2 - The present disclosure provides methods for detecting cell-mediated immunity to SARS-CoV-2 in a subject, methods for detecting a cell-mediated immune response against SARS-CoV-2 in a subject and methods for determining if a vaccine against SARS-CoV-2 elicits a cell-mediated immune response in a subject, comprising administering to the skin of the subject one or more peptides. | 2022-01-20 |
20220016269 | COMPOSITIONS AND METHODS FOR ASSESSING EYE VASCULATURE - Compositions and methods for assessing blood vessels and organs of the body are disclosed herein, specifically methods for assessing the vasculature of the eye. | 2022-01-20 |
20220016270 | RADIOPAQUE MONOMERS, POLYMERS, MICROSPHERES, AND METHODS RELATED THERETO - Radiopaque monomers, polymers, and microspheres are disclosed herein. Methods of using the radiopaque monomers, polymers, and microspheres are disclosed herein. Methods of manufacturing radiopaque monomers, polymers, and microspheres are disclosed herein. | 2022-01-20 |
20220016271 | METHODS FOR TREATING CANCER - The present application provides a method of treating a cancer, including administering to a subject in need of cancer treatment a therapeutically effective amount of an mRNA encoding tumor suppressor protein p53 in combination with an anticancer therapeutic agent, or a pharmaceutically acceptable salt thereof, wherein the anticancer therapeutic agent is selected from an mTOR inhibitor, a platinum-based antineoplastic agent, and an AMPK activating agent. | 2022-01-20 |
20220016272 | COMPOSITIONS, METHODS AND KITS FOR DIAGNOSING AND TREATING CD206 EXPRESSING CELL-RELATED DISORDERS - A method of diagnosing a CD206 expressing cell-related disorder by administering a pharmaceutical composition to a subject, the composition including a carrier molecule having a detectable moiety attached thereto. The carrier molecule has a dextran backbone, and at least one receptor substrate conjugated, directly or indirectly, to the dextran backbone, wherein the receptor substrate is chosen so as to specifically bind to CD206. A method of treating a CD206 expressing cell-related disorder is also provided, as well as an ex vivo method and kit for quantitating the number of cells expressing CD206 in a bodily fluid. | 2022-01-20 |
20220016273 | COMPOSITION FOR DIAGNOSIS OF FUNGAL INFECTION - The present invention provides a composition for diagnosing fungal infection comprising 2-deoxy-2-[ | 2022-01-20 |
20220016274 | RADIOPHARMACEUTICAL AND METHODS - The radiopharmaceutical | 2022-01-20 |
20220016275 | CHELATING AAZTA CONJUGATES AND COMPLEXES THEREOF - A chelating compound of formula (I) or a pharmaceutically acceptable salt thereof and its complexes with metals or radioisotopes thereof. The invention further relates to the preparation of such ligand and complexes as well as to their use as diagnostic or therapeutic agents. | 2022-01-20 |
20220016276 | COMPOSITION COMPRISING CATALASE, PREPARATION METHOD AND USE THEREOF AND METHOD FOR KILLING TUMOR CELLS - A composition comprising catalase, a preparation method and a use thereof, and a method for killing tumor cells are provided. The composition comprises a radionuclide labeled to a biomacromolecule, a soluble alginate and catalase. The composition can be injected into the tumor through an interventional treatment. A gel is formed when an alginate ion in the composition enters the tumor and encounters a calcium ion, such that the radionuclide and the catalase are uniformly confined in the tumor. The composition comprising catalase utilizes catalase to decompose dissolved oxygen generated from hydrogen peroxide in the tumor to advance the hypoxic state of the tumor cells, and the tumor cells are killed with radiation after the hypoxic state thereof has been advanced, and thus the invention has good prospects for applications in cancer therapy. | 2022-01-20 |
20220016277 | MACROCYCLIC COMPLEXES OF RADIONUCLIDES AND THEIR USE IN RADIOTHERAPY OF CANCER - The present technology provides compounds as well as compositions including such compounds useful in targeted radiotherapy of cancer and/or mammalian tissue overexpressing prostate specific membrane antigen (“PSMA”) where the compounds are represented by the following Formulas (I), or a pharmaceutically acceptable salt thereof (IA), or a pharmaceutically acceptable salt thereof (II), or a pharmaceutically acceptable salt thereof, wherein M | 2022-01-20 |
20220016278 | APPARATUS FOR REFLECTING AN INCIDENT RAY OF ELECTROMAGNETIC RADIATION - A flow through photochemistry apparatus and methods of use are disclosed in the present application. One or more reactant materials are passed through a reaction chamber and are exposed to electromagnetic radiation. The reaction chamber has reflective walls arranged to reflect electromagnetic radiation across the volume of the chamber a plurality of times, thereby increasing the probability of the electromagnetic radiation interacting with the reactive materials. The reaction chamber may be used for sterilization and photochemistry applications. | 2022-01-20 |
20220016279 | Disinfection Device and Related Systems and Methods - Disclosed herein are various disinfection devices for disinfecting various objects. Such devices can include a device having a body, at least one light array disposed on an interior surface of the body, and a conveyor disposed within the body. Further disclosed are various methods of disinfecting various objects using such disinfection devices. | 2022-01-20 |
20220016280 | DOOR HANDLE SANITIZING DEVICE - A door handle sanitizing apparatus may include a posterior wall configured to be disposed anterior of and substantially parallel to a door surface and having an inner surface, an arch portion extending in an anterior direction from the posterior wall, the arch portion having an anterior end and an inner surface, a first sanitizing agent source disposed on the posterior wall, and a second sanitizing agent source disposed on the inner surface of the arch portion. | 2022-01-20 |
20220016281 | PHYSICAL USER INTERFACE SANITATION SYSTEM AND METHOD - A touchscreen device sanitation system and method is provided. A touchscreen device is configured with an illumination system that illuminates an external surface of the touchscreen device with ultraviolet light that kills or inactivates disease agents present on the external surface of the touchscreen device. The illumination system may illuminate the external surface of the touchscreen device indirectly from a position within the touchscreen device or directly from a position above the touchscreen device. | 2022-01-20 |
20220016282 | Self-Disinfection Device - A self-disinfection device includes an ultraviolet C (UVC) light-emitting diode (LED) illuminator, which includes a UVC LED chip and a screen. The UVC LED chip that is mounted on a UVC LED package or a heat spreader, which is mounted to a frame of an electronic device. A UVC light emitted by the UVC LED chip is coupled into the screen as a waveguide structure and the UVC light is extracted by a coating or organic medium. | 2022-01-20 |